EP1660658A2 - Utilisation du silencage sirna dans la prevention des metastases - Google Patents

Utilisation du silencage sirna dans la prevention des metastases

Info

Publication number
EP1660658A2
EP1660658A2 EP04816701A EP04816701A EP1660658A2 EP 1660658 A2 EP1660658 A2 EP 1660658A2 EP 04816701 A EP04816701 A EP 04816701A EP 04816701 A EP04816701 A EP 04816701A EP 1660658 A2 EP1660658 A2 EP 1660658A2
Authority
EP
European Patent Office
Prior art keywords
sirna
seq
use according
cells
sirnas
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04816701A
Other languages
German (de)
English (en)
Inventor
Hans Peter B. Prydz
Torgeir Holen
Mohammed Amarzguioui
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SIRNASENSE AS
Original Assignee
Hans Peter B. Prydz
Torgeir Holen
Mohammed Amarzguioui
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from NO20033492A external-priority patent/NO20033492D0/no
Application filed by Hans Peter B. Prydz, Torgeir Holen, Mohammed Amarzguioui filed Critical Hans Peter B. Prydz
Publication of EP1660658A2 publication Critical patent/EP1660658A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification

Abstract

L'invention concerne des ARN de synthèse et plus précisément des petits ARN interférants (siRNA), aptes à moduler l'expression du facteur tissulaire (TF), ainsi que leur utilisation pour prévenir la formation de métastases et traiter le cancer.
EP04816701A 2003-08-06 2004-08-05 Utilisation du silencage sirna dans la prevention des metastases Withdrawn EP1660658A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NO20033492A NO20033492D0 (no) 2003-08-06 2003-08-06 Bruk av siRNA i avstengning av gener for å hindre utvikling av metastaser
US49731403P 2003-08-25 2003-08-25
PCT/NO2004/000238 WO2005040187A2 (fr) 2003-08-06 2004-08-05 Utilisation du silençage sirna dans la prevention des metastases

Publications (1)

Publication Number Publication Date
EP1660658A2 true EP1660658A2 (fr) 2006-05-31

Family

ID=34525618

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04816701A Withdrawn EP1660658A2 (fr) 2003-08-06 2004-08-05 Utilisation du silencage sirna dans la prevention des metastases

Country Status (5)

Country Link
EP (1) EP1660658A2 (fr)
JP (1) JP2007501225A (fr)
AU (1) AU2004284013A1 (fr)
CA (1) CA2534996A1 (fr)
WO (1) WO2005040187A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007006808A1 (fr) * 2005-07-13 2007-01-18 Novo Nordisk Health Care Ag Cellules inactivees proteiques de cellules hotes pour la production de proteines therapeutiques

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE244579T1 (de) * 1997-01-22 2003-07-15 Univ Texas Verfahren und zusammensetzungen des gewebefaktors zur koagulation und behandlung von tumoren
CZ200240A3 (cs) * 1999-07-14 2003-04-16 Novo Nordisk A/S Léčivo s obsahem agonisty nebo antagonisty tkáňového faktoru pro regulaci buněčné migrace
US20050096289A1 (en) * 2002-02-07 2005-05-05 Hans Prydz Methods and compositions for modulating tissue factor
ES2336440T3 (es) * 2002-02-07 2010-04-13 Sirnasense As Silenciamiento portranscripcional de la expresion del factor tisular mediante arn de interferencia cortos.

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AMARZGUIOUI M. ET AL: "Ex vivo and in vivo delivery of anti-tissue factor short interfering RNA inhibits mouse pulmonary metastasis of B16 melanoma cells", CLINICAL CANCER RESEARCH, vol. 12, July 2006 (2006-07-01), pages 4055 - 4061 *
BROMBERG M. ET AL: "Tissue factor promotes melanoma metastasis by a pathway independent of blood coagulation", PROC.NATL.ACAD.SCI., vol. 92, August 1995 (1995-08-01), pages 8205 - 8209 *
Declaration of Pr. Inge Sandlie of the university of Oslo as filed with the letter of 10.08.2006. *

Also Published As

Publication number Publication date
CA2534996A1 (fr) 2005-05-06
WO2005040187A2 (fr) 2005-05-06
JP2007501225A (ja) 2007-01-25
WO2005040187A3 (fr) 2005-09-01
AU2004284013A1 (en) 2005-05-06

Similar Documents

Publication Publication Date Title
AU2019200789B2 (en) Multimeric oligonucleotide compounds
KR101770435B1 (ko) 자연 안티센스 전사체가 아포리포단백질-ａ1로 억제에 의해 아포리포단백-ａ1 관련된 질환의 치료
KR101829469B1 (ko) Ｅｐｏ에 대한 천연 안티센스 전사체의 억제에 의해 에리트로포에틴(ｅｐｏ) 관련된 질환의 치료
KR20200044013A (ko) 아포지단백질 C-III (APOC3)의 발현을 억제하기 위한 RNAi 작용제 및 조성물
EP3573623A1 (fr) Compositions et méthodes d'inhibition de l'expression génique du facteur xii
KR101718297B1 (ko) Ｈｓｆ1-관련 질환을 치료하기 위한 유기 조성물
US20160272970A1 (en) RNA Interference Agents
EP3271482A2 (fr) Compositions et méthodes pour inhiber l'expression génique du facteur xii
TW201505637A (zh) 補體成分Ｃ５ ｉＲＮＡ組成物及其使用方法
US20180282728A1 (en) Organic compositions to treat beta-catenin-related diseases
US20050153918A1 (en) Methods and compositions relating to hnRNP A1, A1B, A2, and B1 nucleic acid molecules
AU2003258183B2 (en) Use of antisense oligonucleotides to inhibit the expression of Akt-1
JP2007510408A (ja) Ｉａｐ核酸塩基オリゴマーおよび核酸塩基オリゴマー複合体ならびにそれらの使用
US20100273998A1 (en) Methods and compositions for modulating tissue factor
AU2003206267B2 (en) Short interfering RNA molecules directed towards a tissue factor coding nucleic acid
WO2005040187A2 (fr) Utilisation du silençage sirna dans la prevention des metastases
EP3237619A1 (fr) Compositions et procédés pour inhiber l'expression de adamts-5 et adam17
WO2023143483A1 (fr) Compositions et procédés pour inhiber l'expression de la protéine prékallikréine (pkk)
US9115167B2 (en) Multi-targets interfering RNA molecules and their applications
OA19513A (en) RNAI agents and compositions for inhibiting expression of apolipoprotein C-lll (APOC3).

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060306

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SIRNASENSE AS

RIN1 Information on inventor provided before grant (corrected)

Inventor name: AMARZGUIOUI, MOHAMMED

Inventor name: PRYDZ, HANS PETER B.

Inventor name: HOLEN, TORGEIR

17Q First examination report despatched

Effective date: 20090212

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090825